RxDoctor Payments Data

Harpreet Bhatia, MD

Cardiovascular Disease · San Diego, CANPI 1750709168

Payments from drug & device makers

$523,094in general payments, 2019–2025

Across 71 payments — averaging $7367.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cleerly, Inc.$497K
  • Kaneka Medical America LLC$11K
  • Novartis$6K
  • Bayer Healthcare LLC$4K
  • Abbott$3K
  • Ionis Pharmaceuticals, Inc.$1K
  • plus $1K from 9 others
$16,656in research payments, 2019–2025

Across 4 payments — averaging $4163.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$17K

What the payments were for

  • Consulting fees$19,95781%
  • Speaking & faculty fees$1,5006%
  • Travel & lodging$2281%
  • Food & beverage$3,05412%
  • Education$260%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$523,094 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$49,336
Medicare patients
291
Services billed
549

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban93$103,301
Repatha SureclickEvolocumab54$37,180
JardianceEmpagliflozin42$36,963
EntrestoSacubitril/Valsartan31$32,120
Repatha PushtronexEvolocumab19$14,451
Praluent PenAlirocumab25$13,890
Repatha SyringeEvolocumab12$10,499
Rosuvastatin Calcium150$2,845
Metoprolol Succinate106$2,073
Ezetimibe78$1,615
Atorvastatin Calcium103$1,341
Carvedilol82$896
Diltiazem 24hr Er (Cd)Diltiazem Hcl34$803
Flecainide Acetate19$723
Amlodipine Besylate65$565

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$76$103,30193 claims
NovartisEntresto$6,246$32,12031 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →